Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg
To Evaluate the Increase of Local Circulation in the Leg Using the Flowaid Device
This is an open label pilot study to evaluate the efficacy and the safety of the Flowaid device in increasing local circulation in the legs.
15 patients with a diagnosis of Peripheral Vascular Disease will be enrolled in this study. They will recieve tratment with the Flowaid device and monitored continuously by means of Laser Doppler Flowmetry as well as by tcPO2 and Digital Thermography. Subjective data will also be collected.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a 15 patient pilot study to evaluate efficacy and safety of use of the Flowaid device in increasing local circulation in the legs of patients with Peripheral Vascular Disease. Patients will be evaluated and scored prior to treatment and then treated with the Flowaid device for a period of two hours. During the treatment period patients will be continuously monitored by digital thermograph as well as by tcPO2 and Laser Doppler Flowmetry. Patients will also be monitored for a brief period immediately after cessation of treatment to evaluate continued effect of the device on local circulation in the leg.
The study will be individually controlled with each patients treated leg evaluated against the contralateral non- treated leg.
Subjective data including distance able to walk, pain and vibratory sensation threshold will also be collected and evaluated appropriately.
Study Type
Study Type
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10035
- New York College of Podiatric Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Give appropriate written informed consent prior to participation in the study
- Have a current diagnosis of Type I or Type II Diabetes Mellitus
- Have an Ankle-Arm Index between 0.35 and 0.8 on the study limb
- Be in reasonable metabolic control, exhibited by HbA1C values of less than12% as observed by serum test results obtained within 3 months prior to the Screening Visit
- Subject and caregiver must be accessible for, and willing to comply with, the safety procedures and available for the 12 week Follow-Up Period
Exclusion Criteria:
- Clinical evidence of gangrene on any part of affected foot
- Active Charcot's foot on the study limb
- Scheduled to undergo vascular surgery, angioplasty, or thrombolysis within 30 days from the end of the study
- Malnourished as evidenced by a pre-albumin of < 11 mg/dL
- Pregnancy or lactating
- History of bleeding disorder
- Participation in another device study for the treatment of Peripheral Vascular Disease 30 days prior to Screening Visit
- Vascular procedures performed 30 days prior to Screening Visit
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Eileen Chusid, PHD, New York College of Podiatric Medicine
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- tali725
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.